WEJO-GROUP-LIMITED
28.2.2023 14:01:37 CET | Business Wire | Press release
Wejo Group Limited (NASDAQ: WEJO), a global leader in Smart Mobility for Good™ cloud and software solutions for connected, electric and autonomous vehicle data, today announced an expanded collaboration with Mercedes-Benz Connectivity Services GmbH. The collaboration will enable Wejo to provide personalized connected vehicle data services for participating cloud-connected fleet vehicles in the E.U. The data Wejo receives will be derived from participating Mercedes-Benz fleet vehicles and processed through Wejo’s ADEPT platform. This data will enable fleet management service (FMS) companies and telematics service providers (TSPs) to utilize data directly from embedded OEM hardware to support fleet services without aftermarket hardware.
Wejo’s collaboration and integration with Mercedes-Benz Connectivity Services is an important milestone in Wejo’s entrance into the fleet management market - anticipated at $38 billion by 2024. Wejo is uniquely positioned to bring multi-OEM fleet data from a single source to FMS companies and TSPs whose customers primarily have mixed OEM fleets. Additionally, providing direct OEM data without aftermarket hardware gives access to richer data sets, reducing fleet downtime by eliminating hardware installs, and the necessity for SIM management.
“With Mercedes-Benz Connectivity Services, we can deliver TSPs and FMS companies more data-driven, enhanced fleet management insights for their fleet customers and help improve safety and drive efficiencies on the roadways,” said Benoit Joly, chief commercial officer at Wejo. “Together, we aim to help customers integrate fleet data into core business processes and derive actionable insights for improved business outcomes.”
The Wejo data from participating Mercedes-Benz fleet vehicles can empower TSPs and FMS companies with the insights needed to inform operations, including geographic locations, fuel insights, odometer and speed readings, and tire pressure. Wejo will have access to driver behavior information that includes the necessary data to promote safe driving. Mercedes-Benz fleet data is shared only at the express request and direction of Mercedes-Benz customers that have expressly agreed to such sharing with Wejo and in following with data protection regulations. Additionally, Wejo ADEPT delivers the highest standards in keeping consumers’ data safe.
“Our customers want the most accurate and direct fleet data in one place with insights to improve the safety and efficiency of their operations,” said Samuel Vals, head of international partnerships at Optimum. “We’re excited to see the collaboration between Mercedes-Benz Connectivity Services and Wejo to deliver direct and actionable OEM insights from Mercedes-Benz vehicles and look forward to additional integrations from Wejo.”
By leveraging driver performance, Wejo’s customers will be able to identify opportunities for improvement and training, ultimately allowing fleet owners peace of mind, knowing that they are leveraging data for the good of their fleets and drivers while protecting their investments and reducing exposure to liability.
About Wejo
Wejo Group Limited is a global leader in cloud and software analytics for connected, electric, and autonomous mobility, revolutionizing the way we live, work and travel by transforming and interpreting historic and real-time vehicle data. The Company enables smarter mobility by organizing trillions of data points from 20.8 million vehicles, of which 13.9 million were active on the platform transmitting data in near real-time, and over 94.6 billion journeys globally as of December 31, 2022, across multiple brands, makes and models, and then standardizing and enhancing those streams of data on a vast scale. Wejo partners with ethical, like-minded companies and organizations to turn that data into insights that unlock value for consumers. With the most comprehensive and trusted data, information, and intelligence, Wejo is creating a smarter, safer, more sustainable world for all. Founded in 2014, Wejo has offices in Manchester, UK and in regions where Wejo does business around the world. For more information, visit www.wejo.com or connect with us on LinkedIn, Twitter, and Instagram.
Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. For more information, please follow this link: https://www.wejo.com/forward-looking-statements
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005320/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom